newsfilter
← Latest News
GlobeNewswire·

Abivax Statement on Short Seller Report

  • Abivax SA issued a statement on November 20, 2026, regarding a short seller report published by Scorpion Capital.
  • The company asserts the report contains numerous factually inaccurate statements, misleading assumptions, & conclusions, including those based on studies commissioned by Scorpion Capital itself.
  • Abivax maintains the integrity of its clinical development program, the results of its Phase 3 ABTECT trials, & the strength of its data to support an FDA NDA filing by the end of 2026.
  • The company highlighted Scorpion Capital's explicit disclosure of a short position & its intention to cover shares after the report, noting the direct financial incentive for a share price decline.
  • Abivax is reviewing the report in detail & anticipates providing further updates regarding the matter.
  • Abivax is a clinical-stage biotechnology company focused on therapeutics for chronic inflammatory diseases, with its lead candidate obefazimod (ABX464) currently in Phase 3 trials for ulcerative colitis.
Company
Abivax
Keywords
Paris Stock Exchange:ABVX, Abivax, American Depositary Shares, Euronext Paris, NASDAQ